Nanobiotix stock rebounds and ranks among the strongest gains in the SBF 120
The Parisian biotech stands out as an exception by posting among the strongest gains in the SBF 120 despite a market under pressure. The security is nevertheless still trading below its short-term moving averages, a technical tension that contrasts with the strength of its one-year performance.
A limited rebound that fails to climb back above moving averages
Nanobiotix gains 1.01% to €33.84 during the session, while the CAC 40 drops 0.36% and the SBF 120 declines in the same proportion. This rebound positions the stock among the strongest gains in the SBF 120, in a market where most of the index is in the red. However, the advance is insufficient to erase the decline of 5.32% recorded over the past week. In terms of moving averages, the situation remains constrained.
The price (€33.84) is below the 20-day MA at €34.93 (gap of -3.12%) and slightly below the 50-day MA at €34.08 (gap of -0.70%). Only the 200-day MA at €27.42 is clearly below the price, with a gap of +23.41%, reflecting the 345.3% gain accumulated over one year. The RSI at 47 is neutral, showing no overbought or oversold configuration, consistent with a security seeking to stabilize after several volatile sessions.
A tense market context amid escalation in the Middle East
Wednesday, September 2nd session opens in a deteriorated geopolitical environment: Iran launched a military strike in response to American installations in Jordan, Iraq and Bahrain, in retaliation for American strikes on its territory. This escalation between Washington and Tehran drives the VIX up 10.25% during the session, to 16.45, signaling a notable increase in risk aversion on markets. The DAX falls 1.02% during the session, the FTSE 100 loses 0.36%.
Nanobiotix, whose high-momentum biotech profile has no direct connection to oil flows or Gulf geopolitics, nevertheless holds its ground in this adverse configuration, which strengthens the visibility of its relative rebound. The technical support at €32.30 remains the downside reference to monitor if selling pressure were to resume, while resistance at €38.60 materializes the first upside obstacle for analysts tracking the file.
